

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TO KNOW. TO ACT.

Mirxes Holding Company Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2629)

**(1) QUARTERLY UPDATE ON BUSINESS OPERATIONS AND
RESUMPTION PROGRESS;
(2) RESIGNATION OF JOINT COMPANY SECRETARIES, CHANGE
OF AUTHORISED REPRESENTATIVE AND PROCESS AGENT, AND
APPOINTMENT OF COMPANY SECRETARY; AND
(3) CONTINUED SUSPENSION OF TRADING**

This announcement is made by Mirxes Holding Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.24A of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Reference is made to the announcements of the Company dated March 31, 2026, April 2, 2026, April 30, 2026, May 10, 2026, July 1, 2026, September 1, 2026 and September 4, 2026 (the “**Announcements**”) in relation to, amongst others, the delay in publication of the 2025 Annual Results, the establishment of the IIC, the suspension of trading in the shares of the Company, the Outstanding Audit Matters, the Initial Resumption Guidance and the Additional Resumption Guidance (collectively, the “**Resumption Guidance**”), the delay in publication of the 2026 Interim Results, and the previous quarterly update on resumption progress. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as defined in the Announcements.

(1) QUARTERLY UPDATE ON BUSINESS OPERATIONS AND RESUMPTION PROGRESS

BUSINESS OPERATIONS

The Group has continued to advance its commercialisation and product development initiatives and has made progress across a number of its diagnostic products and solutions. Set out below are certain key business developments since the Company's previous quarterly update:

FITRAPID™

The Company achieved a significant commercial milestone with the approval from Singapore's Health Sciences Authority (the "**HSA**") of FITRAPID™, its first consumer-facing at-home colorectal cancer screening test in Singapore. Designed as an affordable, non-invasive kit to detect fecal occult blood, an early indicator of lower gastrointestinal tract disease, FITRAPID™ features an all-in-one proprietary device architecture that streamlines sample collection and minimizes user error, delivering clear results in 5 to 10 minutes. This regulatory approval in Singapore follows the momentum from the Thai Food and Drug Administration (the "**TFDA**") approval in Thailand, expanding the Company's reach beyond professional clinical settings and laying the foundation for broader, population-scale adoption of accessible cancer screening solutions. The commercial roll out is planned for the fourth quarter of 2026.

DisCUOver

The Company further strengthened its clinical precision oncology capabilities with the launch of DisCUOver, a clinically validated, tissue-based gene-expression assay designed to accurately predict the tissue-of-origin across 21 tumor types. Utilizing a 90-gene expression profile, the assay addresses the complex diagnostic challenges of Cancers of Unknown Primary (CUP) by empowering oncologists with rapid, actionable insights to guide targeted, site-specific treatment strategies. Developed through a strategic partnership with Canhelp Genomics, DisCUOver is commercially available as of August 2026 as a Laboratory-Developed Test (LDT) at M Diagnostics Pte. Ltd. ("**M Diagnostics**"), the Company's College of American Pathologists accredited ("**CAP-accredited**") clinical laboratory.

CIRRHOClear™

The Company has completed the development, analytical and clinical validation of its key disease early detection product CIRRHOClear™, and has scheduled its commercial launch within 2026. CIRRHOClear™ is a breakthrough non-invasive, blood-based microRNA (“**miRNA**”) test designed to identify liver cirrhosis risk before symptoms appear. Southeast Asia currently bears a severe burden of liver disease, with epidemiological data indicating hundreds of thousands of new incident cases of liver cirrhosis, a major risk factor for liver cancer, in the region annually. Developed from the landmark Early Detection of HCC: miRNA, microbiome and imaging biomarkers in the evolution of chronic liver disease (“**ELEGANCE**”) study in Singapore, which prospectively enrolled over 2,000 subjects at risk of liver cirrhosis and liver cancer, the proprietary assay identifies asymptomatic individuals at high risk of liver cirrhosis with 89% sensitivity and 95% specificity, enabling physicians to intervene proactively before the onset of irreversible liver damage. CIRRHOClear™ will be launched as a primary care screening tool as a LDT, through M Diagnostics, the Company’s CAP accredited clinical laboratory. The Company plans to offer this innovative solution in more countries across the region in the next few months.

STRATEGIC COOPERATION WITH HARBOUR LIFE

The Board announces that the Company is advancing cooperation with Harbour Life Insurance Co., Ltd. (“**Harbour Life**”) for 覓小衛® (GASTROClear™) in health services for insurance clients, individual insurance and group insurance scenarios in China. The proposed cooperation arrangements include: (i) adopting 覓小衛® as a client health, medical and elderly care benefit option of Harbour Life, integrating it into Harbour Life’s priority client service programme and the Le Yang Harbour (樂養港灣) home-based, medical and elderly care scenarios to enrich health service offerings for existing clients; (ii) launching individual insurance pilots, whereby relevant branches will procure the product for agents to offer complimentary use to clients as a health care gesture and auxiliary insurance service tool; (iii) launching group insurance pilots to deliver early screening briefings and product access to corporate employees as a supplementary group health benefit. For cases with abnormal screening results, follow-up will be conducted in compliance with applicable regulations and personal data protection frameworks, combining referrals from medical institutions and Harbour Life’s existing health service arrangements.

The Board is of the view that implementation of the above cooperation will help the Company expand insurance and corporate health channels, extend non-invasive early gastric cancer screening from clinical and physical examination settings to an integrated “screening — health service — insurance coverage” scenario, and improve product reach and institutional procurement stickiness. Favorable pilot outcomes will

enable replication across Harbour Life’s nine provincial branches to build a nationwide insurance channel network. Subject to compliant authorization, the pilots may generate data on screening acceptance, positive case distribution and referrals across populations of varying regions, occupations and age groups, which can inform product education, health economic evidence and the commercialization of multi-cancer pipelines. Harbour Life is a national life insurer incorporated in Qianhai, Shenzhen with state-owned capital backing, and the cooperation will strengthen professional recognition of 覓小衛® within China’s commercial insurance and corporate health scenarios. Certain arrangements remain under discussion or at the pilot stage. The actual procurement volume, pilot scope and service standards shall be subject to formal agreements and practical implementation.

RELEASE OF NHSA’S GUIDELINES FOR ESTABLISHMENT OF LABORATORY TEST ITEMS AND ITS COMMERCIAL IMPACT ON THE COMPANY

I. Background

In August 2026, the National Healthcare Security Administration of China (the “NHSA”) officially issued the Guidelines for the Establishment of Medical Service Price Items for Laboratory Tests (Trial) (《檢驗類醫療服務價格項目立項指南（試行）》) (the “Guidelines”), with an aim to unify the national pricing framework for laboratory test medical services, covering major segments including clinical laboratory testing, molecular diagnostics, biochemistry and immunoassays, with a total of 662 main items, 114 surcharge items and 7 extension items. Centered on service output, the Guidelines implement favorable pricing for high-quality services through a scientifically designed surcharge mechanism, avoiding a “one-size-fits-all” pricing model while reserving room for technological upgrades.

GASTROClear™ adopts fluorescent RT-PCR technology to simultaneously detect 12 gastric cancer-related microRNA (miRNA) biomarkers from a single serum sample. Its technical characteristics fall within the scope of application for the “RNA testing” surcharge item. Based on the item structure and classification logic under the Guidelines, the Group expects GASTROClear™ to be categorized under the main item of “cellular nucleic acid amplification testing” in the charging system and eligible for the “RNA testing” surcharge item.

II. Commercial Impact

The issuance of the Guidelines provides a national-level framework for provincial healthcare security authorities to formulate unified price benchmarks for local laboratory test medical services. This means that when GASTROClear™, as an IVD test item, is deployed in public and private medical institutions, there will be clear pricing basis for its charging pathway. This will assist the Group in advancing hospital access and alignment with charging systems for the product across the China market.

The NHSA stated that it will next guide provincial healthcare security bureaus to formulate province-wide unified price benchmarks with reference to the Guidelines, and coordinated regions will determine the actual implemented prices within such benchmarks. The Group will closely monitor subsequent implementation rules in all provincial medical insurance departments and actively engage in the establishment of the relevant pricing system.

III. Risk Warning

The Guidelines constitute a framework document. Formulation of specific provincial price standards and roll-out of actual implemented price levels will take time, and the final charging standards may vary by region.

RESUMPTION PROGRESS

The Stock Exchange has set out: (i) the following Initial Resumption Guidance (a) to (f) for the Company in its Initial RG Letter dated April 27, 2026; and (ii) an Additional Resumption Guidance in its letter to the Company dated September 1, 2026 (the “**Additional RG Letter**”):

Resumption Guidance (a): conduct an appropriate independent forensic investigation into the Prepayments, the material cash outflows subsequent to December 31, 2025 and any other payments of a similar nature or giving rise to similar concerns, assess the impact on the Company’s business operations and financial position, announce the findings and take appropriate remedial actions

As disclosed in the Company’s announcement dated April 2, 2026, the IIC was established to oversee and supervise the independent investigation for the purpose of addressing the Outstanding Audit Matters. The IIC promptly engaged independent professional advisers (the “**Previous Advisers**”) to commence the investigation thereafter.

As disclosed in the Company's announcement dated April 30, 2026, the Company received the Resumption Guidance detailing requirements on the investigation (the "**Investigation**") and internal control improvement. As part of its ongoing oversight of the Investigation and having obtained legal advice, the IIC reviewed the scope, methodology and proposed further work to be undertaken by the Previous Advisers, taking into account the Resumption Guidance and HKEX Guidance Letter HKEX-GL 120-24. Following discussions with the Previous Advisers regarding the further work required, as well as the expected timetable and fees, the IIC and the Previous Advisers were unable to reach agreement on the arrangements for the next phase of the Investigation. After further negotiations between the parties, the engagements with the Previous Advisers were terminated by mutual consent. The IIC is not aware that the termination was related to any disagreement regarding the findings of the Investigation to date, nor any concern regarding the independence of the Previous Advisers. Rather, it arose from an inability to agree on the commercial and scheduling terms for the next phase of work.

Following the IIC's review and recommendation, the Board approved the engagement of DLA Piper Hong Kong ("**DLA Piper**") and Acclime Corporate Advisory (Hong Kong) Limited ("**Acclime**") (collectively, the "**New Advisers**") as the IIC's legal adviser and forensic accountant, respectively, to assist the IIC in carrying on with the Investigation and aligning its scope and methodology with applicable regulatory guidance.

The IIC and the Board are of the view that the change of advisers is appropriate after considering the requirements of the Resumption Guidance and will facilitate the efficient and effective continuation of the Investigation. When selecting the New Advisers, the New Advisers have also confirmed that none of them has any prior or existing business relationship with the Group that would reasonably be considered to impair its independence in conducting the Investigation, and the IIC had satisfied itself as to their independence and that they possess the requisite experience, credentials and qualifications, expertise and resources to assist the IIC in completing the Investigation. The IIC, among the others, considered the following in their selection: (1) DLA Piper is an international law firm that has registered around 90 partners, consultants, associates and foreign lawyers in their Hong Kong office; (2) the case partner on this engagement has over 26 years of professional experience, specialising in, among other things, advising independent board committees for Hong Kong-listed companies and regulatory compliance on forensic investigations; (3) Acclime has an extensive track record successfully undertaking independent forensic investigations for Hong Kong-listed companies; (4) the engagement lead on this engagement has extensive experience in forensic investigations and will be directly involved in leading the engagement, including reviewing and assessing the work previously undertaken and addressing the outstanding investigation matters; and (5) both New Advisers have committed a team of suitably-qualified staff (together with the possibility to increase the team size if necessary) to complete the tasks within a reasonable working timetable.

During the process of change, the IIC: (i) has requested the Previous Advisers to transfer investigation materials to the New Advisers; (ii) has ensured that the New Advisers are aware of the observations arising from the previous investigation work conducted by the Previous Advisers; (iii) has instructed the New Advisers to perform the necessary procedures to fully address such observations; and (iv) has requested the Board to provide cooperation, resources and assistance to facilitate the effective continuation of the Investigation, which the Board has duly done.

The New Advisers have commenced work on the Investigation, which remains ongoing as at the date of this announcement. Further announcement(s) will be made by the Company regarding the progress of the Investigation as and when appropriate.

Resumption Guidance (b): demonstrate that there is no reasonable regulatory concern about the integrity, competence and/or character of the Group's management and/or any persons with substantial influence over the Company's management and operations, which may pose a risk to investors and damage market confidence

As at the date of this announcement, nothing has come to the attention of the Board which leads to any concern over the integrity, competence and/or character of the Group's management and/or any persons with substantial influence over the Company's management and operations, which may pose a risk to investors and damage market confidence. Further announcement(s) will be made by the Company in relation to the status and development in this regard as and when appropriate.

Resumption Guidance (c): engage an independent internal control consultant to conduct an independent internal control review and demonstrate that (i) the material deficiencies identified in relation to the trading suspension have been rectified and all necessary remedial measures have been implemented; and (ii) the internal controls of the Company are adequate and effective to serve their purposes and enable the issuer to comply with the Listing Rules in all material aspects, including but not limited to financial reporting, disclosure and compliance relating to notifiable and connected transactions and disclosure of material information

As disclosed previously, the Company has engaged PricewaterhouseCoopers Limited ("PwC") as its independent external adviser to carry out an independent Internal Control Review. When selecting PwC, the audit committee of the Company (the "AC") had satisfied itself as to PwC's independence, credentials, qualifications, experience and resources to perform the Internal Control Review, taking into account the fact that: (1) PwC is a member firm of the global PricewaterhouseCoopers network, which spans 136 countries and territories and whose China consulting practice employs over 1,700 professionals; (2) PwC adheres to stringent independence principles in accordance with applicable professional ethical standards. PwC has conducted an independence assessment at both the firm and individual levels and confirmed that, to

the best of its knowledge, no circumstances exist that could reasonably be perceived to impair its objectivity or give rise to self-interest, self-review, familiarity, intimidation, or advocacy threats; (3) the case partner on this engagement has over 20 years of professional experience, specialising in corporate governance, risk management, internal control and regulatory compliance; and (4) PwC has committed a dedicated, senior-led project team comprising five key professionals to complete the tasks within a reasonable working timetable.

The scope of the Internal Control Review is expected to initially cover, amongst other things, procurement, treasury, financial reporting and disclosure, and may expand to other aspects depending on the outcome of the Investigation. As at the date of this announcement, the Internal Control Review is ongoing. The Company will make further announcement(s) as and when there are material developments in relation to the Internal Control Review.

Resumption Guidance (d): publish all outstanding financial results required under the Listing Rules and address any audit modifications

As disclosed in the Announcements, completion of the audit of the 2025 Annual Results is subject to the resolution of the Outstanding Audit Matters, which is in turn subject to the outcome of the Investigation. In view of the further delay of the publication of the 2025 Annual Results as explained above, the preparation of the 2026 Interim Results (including the opening balances) cannot be finalized.

The Company is actively cooperating with the IIC to address the Outstanding Audit Matters so that it can resume work on the 2025 Annual Results, the 2025 Annual Report, the 2026 Interim Results and the 2026 Interim Report as soon as possible. Further announcement(s) will be made by the Company regarding the publication of the 2025 Annual Results and the 2026 Interim Results, and the dispatch of the 2025 Annual Report and the 2026 Interim Report, as and when appropriate.

Resumption Guidance (e): demonstrate the Company's compliance with Rule 13.24 of the Listing Rules

The Group is principally engaged in the research, development, manufacturing and commercialization of molecular diagnostic tests, with a focus on early cancer detection. To the best knowledge of the Directors, as at the date of this announcement, the business operations of the Group are continuing as usual in all material respects. Based on preliminary assessment, the Board is of the view that the Prepayments and the Material Cash Outflows should have no significant adverse impact on the business operations of the Group. On such basis, the Board is of the view that the Group is carrying out, and will continue to carry out, a business with a sufficient level of operations and assets of sufficient value to support its operations to warrant the continued listing of the Company's shares.

Resumption Guidance (f): inform the market of all material information for the Shareholders and investors to appraise the Company's position

Since the suspension of trading in the shares of the Company, the Company has been updating the Shareholders and potential investors with material information on a regular basis by way of announcements. The Company is working closely with its professional advisers and taking appropriate steps to fulfill the Resumption Guidance, and will update the Shareholders and potential investors of all material information of the Company as and when appropriate.

Additional Resumption Guidance: re-comply with Rule 13.92(2) of the Listing Rules

As a result of the resignation of Dr. Lam on August 31, 2026, the Company is unable to comply with the following requirements under the Listing Rules: (a) the requirement under Rule 13.92(2) of the Listing Rules to have directors of different genders on the board; and (b) the requirement under paragraph B.3.5 of the Corporate Governance Code as set out in Appendix C1 to the Listing Rules which stipulates that the listed issuer must appoint at least one director of a different gender to the nomination committee. The Company is in the process of identifying a suitable female candidate to be appointed to the Board and the Nomination Committee as soon as practicable, and in any event within three months from the date of resignation of Dr. Lam in order to ensure compliance by the Company with the requirements of the Listing Rules as set out above. Further announcement(s) will be made by the Company in this regard as and when appropriate.

(2) RESIGNATION OF JOINT COMPANY SECRETARIES, CHANGE OF AUTHORISED REPRESENTATIVE AND PROCESS AGENT, AND APPOINTMENT OF COMPANY SECRETARY

The Board announces that, with effect from September 30, 2026, Ms. SIOW Yuet Chew, Grace (“**Ms. Siow**”) has tendered her resignation as (i) a joint company secretary of the Company (“**Joint Company Secretary(ies)**”); (ii) an authorised representative of the Company (the “**Authorised Representative**”) for the purpose of Rule 3.05 of the Listing Rules; and (iii) the representative for acceptance of service of process and notices on behalf of the Company in Hong Kong pursuant to Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Process Agent**”), due to a change in work arrangement at Vistra, the Company’s corporate secretarial service provider. Ms. OUYONG Wei Zhi, Vitoria (“**Ms. Owyong**”) has tendered her resignation as a Joint Company Secretary with effect from the same date in order to devote more time to her other responsibilities within the Group.

Each of Ms. Siow and Ms. Owyong has confirmed that there are no matters that need to be brought to the attention of the shareholders of the Company or the Stock Exchange in relation to their respective resignations.

Ms. PUN Ka Ying, Elaine (“**Ms. Pun**”) has been appointed as the company secretary of the Company (“**Company Secretary**”), Authorised Representative and Process Agent with effect from September 30, 2026. Ms. Pun has over 15 years of corporate secretarial experience and holds a bachelor’s degree in Social Science from The Chinese University of Hong Kong in 1999, and is a Chartered Secretary, a Chartered Governance Professional and an associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom. The Board considers that she satisfies the requirements under Rule 3.28 of the Listing Rules.

The Board would like to take this opportunity to express its sincere gratitude to Ms. Siow and Ms. Owyong for their contribution to the Company during their tenure of service, and extends a warm welcome to Ms. Pun on her new appointment.

(3) CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on April 1, 2026 and will remain suspended pending the fulfillment of the Resumption Guidance as specified by the Stock Exchange.

By Order of the Board
Mirxes Holding Company Limited
Dr. ZHOU Lihan
Executive Director and Chief Executive Officer

Hong Kong, October 1, 2026

As of the date of this announcement, the Board comprises (i) Dr. ZHOU Lihan and Dr. ZOU Ruiyang as executive Directors; (ii) Dr. TOO Heng Phon, Dr. LE Beilin and Mr. LIU Da as non-executive Directors; and (iii) Mr. FANG Xiao, Mr. TSANG Kwok Wai and Mr. CHOW Shiu Wing Joseph as independent non-executive Directors.